세계 수막염균 백신 시장 조사 보고서 : 산업 분석, 규모, 점유율, 성장, 동향 예측(2024-2032년)

The global demand for Meningococcal Vaccine Market is presumed to reach the market size of nearly USD 10.28 Billion by 2032 from USD 5.57 Billion in 2023 with a CAGR of 7.05% under the study period 2024-2032.

Meningococcal vaccine helps prevent meningococcal disease. The meningococcal disease is caused by Neisseria meningitides bacteria. The vaccines contain antigens substances that boost the body's immune system and cause it to make antibodies, these antibodies then protect the body by attacking and killing the bacteria. The vaccine is given either by injection into a muscle or just under the skin. There are three types of meningococcal vaccines available: Polysaccharide vaccines, conjugate vaccines, and protein based vaccine.

MARKET DYNAMICS

Growing incidence of meningococcal meningitis is driving the growth of market. Meningococcal disease is potentially fatal, observed worldwide with reportable condition in all states, but the highest burden of the disease is in the sub-Saharan Africa, stretching from Senegal in the west to Ethiopia in the east.Market is predicted to experience new waves in the growth owing to the COVID-19, an emerging an rapidly evolving situation.Scientist across the world are focused on discovering vaccine for coronavirus. Various clinical trials are executed to determine the results. Number of drugs and vaccine is identified as candidate to eradicate COVID-19. ChAdOx1 nCoV-19, vaccine against meningococcal disease is among the one. This vaccine acts by priming the immune system to recognize and attack the coronavirus, stimulating a T-cell response and has appeared to be safe in animal and early-stage human testing, giving confidence for the coronavirus version and market growth.

The research report covers Porter's Five Forces Model, Market Attractiveness Analysis, and Value Chain analysis. These tools help to get a clear picture of the industry's structure and evaluate the competition attractiveness at a global level. Additionally, these tools also give an inclusive assessment of each segment in the global market of Meningococcal Vaccine. The growth and trends of Meningococcal Vaccine industry provide a holistic approach to this study.

MARKET SEGMENTATION

This section of the Meningococcal Vaccine market report provides detailed data on the segments at country and regional level, thereby assisting the strategist in identifying the target demographics for the respective product or services with the upcoming opportunities.

By Type

• Bivalent
• Quadrivalent
• Others

By Brand

• Menactra
• Menveo
• Nimenrix
• Trumenba
• Bexsero
• Others

By Age Group

• Infants (0 to 2 years)
• Children and Adults (2 years & above)

By Serotype

• Serotype A
• Serotype B
• Serotype C
• Serotype W-135
• Serotype Y

By Sales Channel

• Private
• Public

REGIONAL ANALYSIS

This section covers the regional outlook, which accentuates current and future demand for the Meningococcal Vaccine market across North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. Further, the report focuses on demand, estimation, and forecast for individual application segments across all the prominent regions.

The research report also covers the comprehensive profiles of the key players in the market and an in-depth view of the competitive landscape worldwide. The major players in the Meningococcal Vaccine market include Pfizer Inc., Sanofi, Serum Institute Of India Ltd., GSK Plc., Merck & Co. Inc., Walvax Biotechnology Co. Ltd. This section consists of a holistic view of the competitive landscape that includes various strategic developments such as key mergers & acquisitions, future capacities, partnerships, financial overviews, collaborations, new product developments, new product launches, and other developments.

In case you have any custom requirements, do write to us. Our research team can offer a customized report as per your need.

TABLE OF CONTENTS

1. PREFACE

• 1.1. Report Description
  • 1.1.1 Objective
  • 1.1.2 Target Audience
  • 1.1.3 Unique Selling Proposition (USP) & offerings
• 1.2. Research Scope
• 1.3. Research Methodology
  • 1.3.1 Market Research Process
  • 1.3.2 Market Research Methodology

2. EXECUTIVE SUMMARY

• 2.1. Highlights of Market
• 2.2. Global Market Snapshot

3. MENINGOCOCCAL VACCINE - INDUSTRY ANALYSIS

• 3.1. Introduction - Market Dynamics
• 3.2. Market Drivers
• 3.3. Market Restraints
• 3.4. Opportunities
• 3.5. Industry Trends
• 3.6. Porter's Five Force Analysis
• 3.7. Market Attractiveness Analysis
  • 3.7.1 Market Attractiveness Analysis By Type
  • 3.7.2 Market Attractiveness Analysis By Brand
  • 3.7.3 Market Attractiveness Analysis By Age Group
  • 3.7.4 Market Attractiveness Analysis By Serotype
  • 3.7.5 Market Attractiveness Analysis By Sales Channel
  • 3.7.6 Market Attractiveness Analysis By Region

4. VALUE CHAIN ANALYSIS

• 4.1. Value Chain Analysis
• 4.2. Raw Material Analysis
  • 4.2.1 List of Raw Materials
  • 4.2.2 Raw Material Manufactures List
  • 4.2.3 Price Trend of Key Raw Materials
• 4.3. List of Potential Buyers
• 4.4. Marketing Channel
  • 4.4.1 Direct Marketing
  • 4.4.2 Indirect Marketing
  • 4.4.3 Marketing Channel Development Trend

5. GLOBAL MENINGOCOCCAL VACCINE MARKET ANALYSIS BY TYPE

• 5.1. Overview By Type
• 5.2. Historical and Forecast Data
• 5.3. Analysis By Type
• 5.4. Bivalent Historic and Forecast Sales By Regions
• 5.5. Quadrivalent Historic and Forecast Sales By Regions
• 5.6. Others Historic and Forecast Sales By Regions

6. GLOBAL MENINGOCOCCAL VACCINE MARKET ANALYSIS BY BRAND

• 6.1. Overview By Brand
• 6.2. Historical and Forecast Data
• 6.3. Analysis By Brand
• 6.4. Menactra Historic and Forecast Sales By Regions
• 6.5. Menveo Historic and Forecast Sales By Regions
• 6.6. Nimenrix Historic and Forecast Sales By Regions
• 6.7. Trumenba Historic and Forecast Sales By Regions
• 6.8. Bexsero Historic and Forecast Sales By Regions
• 6.9. Others Historic and Forecast Sales By Regions

7. GLOBAL MENINGOCOCCAL VACCINE MARKET ANALYSIS BY AGE GROUP

• 7.1. Overview By Age Group
• 7.2. Historical and Forecast Data
• 7.3. Analysis By Age Group
• 7.4. Infants (0 to 2 years) Historic and Forecast Sales By Regions
• 7.5. Children and Adults (2 years & above) Historic and Forecast Sales By Regions

8. GLOBAL MENINGOCOCCAL VACCINE MARKET ANALYSIS BY SEROTYPE

• 8.1. Overview By Serotype
• 8.2. Historical and Forecast Data
• 8.3. Analysis By Serotype
• 8.4. Serotype A Historic and Forecast Sales By Regions
• 8.5. Serotype B Historic and Forecast Sales By Regions
• 8.6. Serotype C Historic and Forecast Sales By Regions
• 8.7. Serotype W-135 Historic and Forecast Sales By Regions
• 8.8. Serotype Y Historic and Forecast Sales By Regions

9. GLOBAL MENINGOCOCCAL VACCINE MARKET ANALYSIS BY SALES CHANNEL

• 9.1. Overview By Sales Channel
• 9.2. Historical and Forecast Data
• 9.3. Analysis By Sales Channel
• 9.4. Private Historic and Forecast Sales By Regions
• 9.5. Public Historic and Forecast Sales By Regions

10. GLOBAL MENINGOCOCCAL VACCINE MARKET ANALYSIS BY GEOGRAPHY

• 10.1. Regional Outlook
• 10.2. Introduction
• 10.3. North America Sales Analysis
  • 10.3.1 Overview, Historic and Forecast Data Sales Analysis
  • 10.3.2 North America By Segment Sales Analysis
  • 10.3.3 North America By Country Sales Analysis
  • 10.3.4 United States Sales Analysis
  • 10.3.5 Canada Sales Analysis
  • 10.3.6 Mexico Sales Analysis
• 10.4. Europe Sales Analysis
  • 10.4.1 Overview, Historic and Forecast Data Sales Analysis
  • 10.4.2 Europe By Segment Sales Analysis
  • 10.4.3 Europe By Country Sales Analysis
  • 10.4.4 United Kingdom Sales Analysis
  • 10.4.5 France Sales Analysis
  • 10.4.6 Germany Sales Analysis
  • 10.4.7 Italy Sales Analysis
  • 10.4.8 Russia Sales Analysis
  • 10.4.9 Rest Of Europe Sales Analysis
• 10.5. Asia Pacific Sales Analysis
  • 10.5.1 Overview, Historic and Forecast Data Sales Analysis
  • 10.5.2 Asia Pacific By Segment Sales Analysis
  • 10.5.3 Asia Pacific By Country Sales Analysis
  • 10.5.4 China Sales Analysis
  • 10.5.5 India Sales Analysis
  • 10.5.6 Japan Sales Analysis
  • 10.5.7 South Korea Sales Analysis
  • 10.5.8 Australia Sales Analysis
  • 10.5.9 South East Asia Sales Analysis
  • 10.5.10 Rest Of Asia Pacific Sales Analysis
• 10.6. Latin America Sales Analysis
  • 10.6.1 Overview, Historic and Forecast Data Sales Analysis
  • 10.6.2 Latin America By Segment Sales Analysis
  • 10.6.3 Latin America By Country Sales Analysis
  • 10.6.4 Brazil Sales Analysis
  • 10.6.5 Argentina Sales Analysis
  • 10.6.6 Peru Sales Analysis
  • 10.6.7 Chile Sales Analysis
  • 10.6.8 Rest of Latin America Sales Analysis
• 10.7. Middle East & Africa Sales Analysis
  • 10.7.1 Overview, Historic and Forecast Data Sales Analysis
  • 10.7.2 Middle East & Africa By Segment Sales Analysis
  • 10.7.3 Middle East & Africa By Country Sales Analysis
  • 10.7.4 Saudi Arabia Sales Analysis
  • 10.7.5 UAE Sales Analysis
  • 10.7.6 Israel Sales Analysis
  • 10.7.7 South Africa Sales Analysis
  • 10.7.8 Rest Of Middle East And Africa Sales Analysis

11. COMPETITIVE LANDSCAPE OF THE MENINGOCOCCAL VACCINE COMPANIES

• 11.1. Meningococcal Vaccine Market Competition
• 11.2. Partnership/Collaboration/Agreement
• 11.3. Merger And Acquisitions
• 11.4. New Product Launch
• 11.5. Other Developments

12. COMPANY PROFILES OF MENINGOCOCCAL VACCINE INDUSTRY

• 12.1. Top Companies Market Share Analysis
• 12.2. Market Concentration Rate
• 12.3. Pfizer Inc.
  • 12.3.1 Company Overview
  • 12.3.2 Company Revenue
  • 12.3.3 Products
  • 12.3.4 Recent Developments
• 12.4. Sanofi
  • 12.4.1 Company Overview
  • 12.4.2 Company Revenue
  • 12.4.3 Products
  • 12.4.4 Recent Developments
• 12.5. Serum Institute Of India Ltd.
  • 12.5.1 Company Overview
  • 12.5.2 Company Revenue
  • 12.5.3 Products
  • 12.5.4 Recent Developments
• 12.6. GSK Plc.
  • 12.6.1 Company Overview
  • 12.6.2 Company Revenue
  • 12.6.3 Products
  • 12.6.4 Recent Developments
• 12.7. Merck & Co. Inc.
  • 12.7.1 Company Overview
  • 12.7.2 Company Revenue
  • 12.7.3 Products
  • 12.7.4 Recent Developments
• 12.8. Walvax Biotechnology Co. Ltd
  • 12.8.1 Company Overview
  • 12.8.2 Company Revenue
  • 12.8.3 Products
  • 12.8.4 Recent Developments

Note - In company profiling, financial details and recent developments are subject to availability or might not be covered in the case of private companies